CAPR | Ticker Profile - Titan Protect

CAPR

Capricor Therapeutics, Inc.

Healthcare · Biotechnology · NMS

$26.71

Data: 2026-05-28

✗ ETHICAL FAIL

Unknown MOAT

MODERATE

Data Confidence: 71.4%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$1.7B

Total market value of the company

Trailing P/E

N/A

Forward P/E

-38.15

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

-56.4%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$54.00

+102% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 9 analysts covering this stock

About Capricor Therapeutics, Inc.

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California.

https://www.capricor.com

Country: United States Employees: 231 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% N/A

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.890

Good returns relative to risk taken

Kelly Fraction

0.1423

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

1.633

Returns exceed worst-case losses — strong risk profile

Annual Return

129.1%

Historical annualised return based on price data

Max Drawdown

-79.1%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

100

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.48

Very low correlation to market moves

52W High

$40.37

34% below the year high

52W Low

$4.30

521% above the year low

Avg Volume

1,261,478

Average daily shares traded — higher means easier to buy and sell

Short Ratio

10.1

Days it would take all short sellers to cover — higher means more crowded

Short % Float

20.8%

Very high short interest — potential squeeze candidate

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-2.32

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

5.31

Heavy leverage — higher financial risk if revenues decline

Current Ratio

8.42

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

8.28

Like current ratio but excludes inventory — stricter test

Gross Margin

0.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

0.0%

Profit from core operations before interest and tax

Free Cash Flow

$-70,473,720

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-114,593,696

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$63.00

Target Median

$54.00

Target Low

$38.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go